Waystar Lags Peers on Options and Insider Activity Ahead of Earnings

WAY diverged from its closest peers this past week, falling 2.7% to $28.02 while the median peer move was roughly flat. Among the most correlated names, PHR gained 2% on the week and VEEV slipped just 1.6%. CERT stood out in the other direction, up nearly 12%.

Options positioning on WAY has swung more aggressively toward calls than any point in recent months, making it the standout market signal this week. The put/call ratio dropped to 0.53, more than two standard deviations below its 20-day average of 0.59. That is the most call-heavy reading in at least a year, and it sits closer to the 52-week low of 0.34 than to the 52-week high of 1.32. Options traders have rarely been this tilted toward upside ahead of a WAY print.

Short interest tells a less aggressive story than the monthly trend implies. Bears trimmed positions through the week, with SI falling around 5% to 16.2 million shares, or 8.5% of the free float. That still leaves a meaningful short book: a month ago, the same figure was closer to 7.7%. Borrow availability has tightened alongside that build, dropping from roughly 224% in mid-September to 143% now, though it remains loose enough that new short positions can be put on without friction. Cost to borrow is 0.57%, up 26% on the week but still low in absolute terms. Nothing in the lending market points to squeeze pressure.

The insider register adds a layer of caution worth noting. The 90-day net position across SEC Form 4 filings runs to about 247,500 shares sold, worth roughly $6.4 million. The largest single transaction was CEO Matthew Hawkins selling $2.2 million of stock on October 6, executed under a pre-arranged 10b5-1 plan. Planned sales carry less signal than discretionary ones, and Hawkins has run the same exercise-and-sell pattern in both October and September. Also on the register: CFO Alpana Wegner had 3,409 shares withheld for tax on October 23, a compensation mechanic rather than a market view. Advent International remains on the 13D activist register at a 5.8% stake, as last disclosed in October 2025. That filing carries the standard caveat: stakes are event-driven disclosures around the 5% threshold, and holders may fall below without a further filing.

The analyst community is broadly positive but not without division. Keybanc lifted its target to $35 from $30 on October 16, maintaining Overweight. The consensus mean sits at $34.09 against a current price of $28.02, implying roughly 22% upside if the Street proves right. Barclays moved in the opposite direction in September, downgrading to Equal-Weight while raising its target to $30. That downgrade reflects the bear case: elongated enterprise sales cycles, a high share of volume-based revenue, and the risk that growth normalizes after a one-time boost from the Change Healthcare disruption in 2024. The bull case rests on 30,000-plus clients, more than 5,000 payor connections, and management's guidance of low-double-digit growth with 40%-plus adjusted EBITDA margins.

Earnings are due November 2. The prior three prints each produced a negative first-day move: down 4.7%, 13.9%, and 11.6% respectively. The five-day trajectory was more mixed, with one recovery and two extended declines. Given that history, the call-heavy positioning looks either well-timed conviction or a setup that requires the print to break the pattern.